Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 1432
interventional 1295
Observational 132
Registry 5

Studies over Time

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Behavioral 492
Other 213
Drug|placebo 125
Dietary Supplement 119
Dietary Supplement|placebo 79
Drug 70
Behavioral|Other 49
Device 19
Dietary Supplement|Other 16
Other|placebo 13
Procedure 13
Device|placebo 12
Behavioral|Drug 11
Behavioral|Device 10
Behavioral|Dietary Supplement 8
Device|Other 7
Drug|Other|placebo 6
Behavioral|Drug|placebo 5
Behavioral|Dietary Supplement|Other 3
Behavioral|Dietary Supplement|placebo 3
Combination Product 3
Device|Drug 3
Diagnostic Test 2
Drug|Procedure 2
Behavioral|Device|Other 1
Behavioral|Dietary Supplement|Other|placebo 1
Biological|Other 1
Biological|placebo 1
Device|Dietary Supplement 1
Device|Drug|placebo 1
Dietary Supplement|Drug 1
Dietary Supplement|Other|placebo 1
Drug|Other 1
Drug|Other|placebo|Radiation 1
Genetic|Other 1
placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Weekly studies for each intervention

Studies by Country

Country Study_Count
United States 631
NA 106
Canada 58
Germany 46
Spain 38
United Kingdom 34
Netherlands 31
Denmark 27
France 27
Norway 24
China 22
Iran, Islamic Republic of 19
Italy 19
Sweden 19
Brazil 17
Mexico 14
Korea, Republic of 12
Switzerland 9
Malaysia 8
Israel 7
Finland 6
Poland 6
Colombia 5
Greece 5
India 5
Portugal 5
Belgium 4
Hong Kong 4
Australia 3
Egypt 3
Taiwan 3
Thailand 3
Chile 2
Cuba 2
Germany|Italy 2
Ireland 2
Jordan 2
Lithuania 2
Qatar 2
Saudi Arabia 2
United States|Canada 2
United States|Puerto Rico 2
United States|United Kingdom 2
Australia|New Zealand 1
Austria 1
Bangladesh 1
Belgium|Denmark|Finland|Germany|Netherlands|Sweden|United Kingdom 1
Belgium|Singapore 1
Bolivia 1
Brunei Darussalam 1
Czechia|Denmark|Italy 1
Ecuador 1
Finland|Netherlands|Sweden 1
Finland|Sweden 1
Germany|Hungary|United Kingdom 1
Germany|Switzerland 1
Germany|United Kingdom 1
Greece|Hungary|Italy|Spain 1
Indonesia 1
Japan 1
Japan|Korea, Republic of 1
Lebanon 1
Netherlands|Sweden|United Kingdom 1
New Zealand 1
Nigeria 1
Romania 1
Romania|Spain|Sweden 1
Singapore 1
Tunisia 1
Turkey 1
Ukraine|United States|Denmark|Israel|Netherlands|Portugal|South Africa|Spain|Sweden|Switzerland 1
United States|Algeria|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Colombia|Croatia|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|India|Ireland|Israel|Italy|Japan|Latvia|Malaysia|Mexico|Netherlands|Norway|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Serbia|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Algeria|Argentina|Canada|Germany|Greece|India|Japan|Puerto Rico|Russian Federation|South Africa|Spain|United Arab Emirates|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|Former Serbia and Montenegro|France|Germany|Hong Kong|Hungary|India|Ireland|Israel|Italy|Mexico|Netherlands|Norway|Poland|Russian Federation|Serbia|South Africa|Spain|Switzerland|Turkey|United Kingdom 1
United States|Argentina|Belgium|Bulgaria|Canada|Denmark|Finland|France|Germany|India|Japan|Mexico|Poland|Puerto Rico|Russian Federation|Taiwan|United Kingdom 1
United States|Argentina|Brazil|China|India|Japan|Mexico|Puerto Rico|Russian Federation|Taiwan 1
United States|Argentina|Colombia|Finland|Germany|Italy|Russian Federation|Spain|Sweden 1
United States|Australia 1
United States|Australia|Bahamas|Canada|Chile|Mexico|New Zealand|Poland 1
United States|Austria|Belgium|Croatia|Ireland|Mexico|Russian Federation|United Kingdom 1
United States|Austria|Canada|Czechia|Hungary|Slovakia|United Kingdom 1
United States|Belgium 1
United States|Brazil|United Kingdom 1
United States|Bulgaria|Canada|Czechia|Germany|Mexico|Russian Federation|Slovakia 1
United States|Canada|Czechia|Denmark|Hungary|Italy|Poland|United Kingdom 1
United States|Canada|Czechia|Denmark|Italy|Spain 1
United States|Canada|Denmark|Finland|Ireland|Japan|Poland|Serbia|South Africa|United Kingdom 1
United States|Canada|Denmark|Germany|Italy 1
United States|Canada|Germany|Israel|Italy|Mexico|Turkey 1
United States|Canada|Hungary|Italy|Spain 1
United States|Czechia|Denmark|Italy|Spain 1
United States|France|Germany|India|Israel|Italy|Puerto Rico|South Africa|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Germany 1
United States|Israel 1
United States|Sweden 1
Vietnam 1

Sites per Study

Site_count Study_Count
1 1103
2 87
3 21
4 15
5 6
6 6
7 1
8 3
9 4
10 3
11 1
12 2
13 3
15 2
16 4
17 2
18 2
19 1
23 1
25 1
27 1
29 1
30 1
32 1
34 3
36 4
38 1
40 1
44 1
53 1
54 1
55 1
72 1
83 1
119 1
125 1
131 1
150 1
161 1
226 1
499 1
806 1

Phase

Phase Study_Count
N/A 964
Phase 2 87
Phase 1 85
Phase 3 60
Phase 4 54
Phase 1/Phase 2 21
Phase 2/Phase 3 16
Early Phase 1 8

Number of Arms

Number_of_Arms Count_of_Studies
1 142
2 757
3 209
4 93
5 17
6 13
7 5
8 5
12 2
13 1
NA 51

Number of Updates

Count of Versions Count of Studies
1 198
2 234
3 182
4 175
5 119
6 92
7 66
8 48
9 27
10 35
11 28
12 20
13 8
14 4
15 7
16 9
17 3
18 5
19 4
20 5
21 1
22 1
23 1
25 1
26 1
27 1
31 3
32 1
33 1
39 1
40 2
41 1
48 1
51 1
57 1
60 1
80 1
86 1
89 1
104 1
125 1
131 1
133 1

Update History Change Type

Change Type Count_of_Changes Count_of_Studies ratio
Study Status 5858 1097 5.340018
Contacts/Locations 2069 855 2.419883
Recruitment Status 1613 903 1.786268
None (earliest Version on record) 1295 1295 1.000000
Study Design 1073 763 1.406291
Outcome Measures 770 491 1.568228
Study Description 726 339 2.141593
Sponsor/Collaborators 539 375 1.437333
Arms 538 374 1.438503
Interventions 538 374 1.438503
Eligibility 535 339 1.578171
Study Identification 404 279 1.448029
Oversight 270 236 1.144068
References 233 142 1.640845
Conditions 192 159 1.207547
More Information 123 63 1.952381
IPDSharing 120 113 1.061947
Results 96 96 1.000000
Documents 49 38 1.289474
Baseline Characteristics 44 32 1.375000
Results Submission Events 44 44 1.000000
Reported Adverse Events 37 33 1.121212
Participant Flow 31 27 1.148148
2020 Outcome Measures 1 1 1.000000
2020 Study Status 1 1 1.000000
Quality Control Review has not concludedReturned: June 19 1 1 1.000000
Quality Control Review has not concludedReturned: May 27 1 1 1.000000

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 10.000 2.0000 2.00000 10.00000 3.0000 10.0000 12.0000 20.0000
1st Qu. 22.750 40.0000 31.00000 31.00000 40.0000 58.2500 82.0000 50.0000
Median 51.500 76.0000 56.00000 66.00000 77.0000 98.5000 192.0000 70.5000
Mean 320.375 380.7229 65.01176 79.66667 148.3765 104.1875 948.9661 389.5556
3rd Qu. 315.750 148.5000 84.00000 113.00000 152.0000 122.5000 551.5000 116.7500
Max. 1300.000 65278.0000 320.00000 225.00000 1700.0000 340.0000 17500.0000 14673.0000

Trial Group Type

group_type Group_Count
Experimental 1648
Active Comparator 598
Placebo Comparator 359
No Intervention 197
Other 109
NA 51
Sham Comparator 19

Intervention Model

intervention_model Study_Count
Parallel Assignment 909
Single Group Assignment 164
Crossover Assignment 157
Factorial Assignment 50
Sequential Assignment 9
NA 6

Primary Purpose

primary_purpose Study_Count
Treatment 680
Prevention 322
Basic Science 106
Other 76
Supportive Care 39
NA 35
Health Services Research 27
Diagnostic 7
Screening 3

Observational Studies

Studies by Country

Country Study_Count
United States 48
NA 15
Denmark 10
Italy 9
Canada 6
Netherlands 6
Switzerland 5
China 4
United Kingdom 4
Germany 2
Mexico 2
Norway 2
Argentina|Brazil|Chile|Colombia|Costa Rica|Ecuador|Peru|Venezuela 1
Australia 1
Austria 1
Belgium 1
Brazil 1
Finland 1
France 1
Greece 1
Hong Kong 1
Israel 1
Kazakhstan|Russian Federation 1
Korea, Republic of 1
Malawi 1
Malaysia 1
Morocco|Tunisia 1
Russian Federation 1
Saudi Arabia 1
Spain 1
Sweden 1

Sites per Study

Site_count Study_Count
1 119
2 5
3 1
4 1
5 1
6 1
8 1
11 1
27 1
66 1

Number of Updates

Count of Versions Count of Studies
1 26
2 36
3 20
4 11
5 9
6 4
7 4
8 3
9 1
10 2
11 1
12 2
13 1
14 3
16 1
29 1
52 1
65 1
76 1
100 1
132 1
133 1
147 1

Update History Change Type

Change Type Count_of_Changes Count_of_Studies ratio
Study Status 1058 106 9.981132
Study Description 225 33 6.818182
Contacts/Locations 176 60 2.933333
None (earliest Version on record) 132 132 1.000000
Study Design 123 66 1.863636
Recruitment Status 103 71 1.450704
Eligibility 77 30 2.566667
Outcome Measures 64 41 1.560976
Sponsor/Collaborators 49 36 1.361111
References 44 21 2.095238
Study Identification 34 28 1.214286
Conditions 27 15 1.800000
Oversight 24 19 1.263158
Groups 23 19 1.210526
Interventions 23 19 1.210526
IPDSharing 3 3 1.000000
More Information 2 1 2.000000
Results 2 2 1.000000
Results Submission Events 2 2 1.000000
Baseline Characteristics 1 1 1.000000
Documents 1 1 1.000000
Participant Flow 1 1 1.000000
Reported Adverse Events 1 1 1.000000

Enrollment Metrics

Measure Observational
Min 1.00
1st Qu 49.25
Median 148.00
Mean 762327.13
3rd Qu 602.25
Max 99999999.00

Observation Model

observational_model Study_Count
Cohort 66
Other 18
NA 13
Case-Control 12
Case-Only 8
Case Control 6
Ecologic or Community 4
Case-Crossover 3
Family-Based 2

Time Perspective

time_perspective Study_Count
Prospective 79
Cross-Sectional 32
Retrospective 14
Other 5
NA 2

Registries

Studies by Country

Country Study_Count
United States 4
Colombia 1

Sites per Study

Site_count Study_Count
1 4
28 1

Number of Updates

Count of Versions Count of Studies
1 1
2 1
4 1
8 1
9 1

Update History Change Type

Change Type Count_of_Changes Count_of_Studies ratio
Study Status 19 4 4.75
Contacts/Locations 7 4 1.75
None (earliest Version on record) 5 5 1.00
Recruitment Status 5 4 1.25
Sponsor/Collaborators 5 2 2.50
Eligibility 2 2 1.00
Groups 2 1 2.00
Interventions 2 1 2.00
Study Description 2 2 1.00
Outcome Measures 1 1 1.00
Oversight 1 1 1.00
Study Identification 1 1 1.00

Enrollment Metrics

Measure Registries
Min 60
1st Qu 80
Median 100
Mean 2070
3rd Qu 110
Max 10000

Registry Model

observational_model Study_Count
Case-Only 2
Cohort 2
Other 1

Time Perspective

time_perspective Study_Count
Prospective 3
Cross-Sectional 2

Follow-up

target_duration Study_Count
1 Year 1
16 Weeks 1
3 Months 1
6 Months 1
7 Days 1